Premium
Gonadal status and outcome of bariatric surgery in obese men
Author(s) -
Aarts Edo,
Wageningen Bas,
Loves Sandra,
Janssen Ignace,
Berends Frits,
Sweep Fred,
Boer Hans
Publication year - 2014
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12366
Subject(s) - medicine , hypogonadotrophic hypogonadism , obesity , weight loss , morbidly obese , testosterone (patch) , surgery , endocrinology , hormone
Summary Background Obesity‐related hypogonadotrophic hypogonadism ( O r HH ) occurs in over 40% of morbidly obese men. Obesity‐related hypogonadotrophic hypogonadism may reduce the beneficial effects of bariatric surgery. Objective To assess the impact of O r HH on the outcome of bariatric surgery in men. Patients and methods Observational study with measurement of serum gonadal hormones, and assessment of body composition, glucose, lipid and bone metabolism during the first year after bariatric surgery in 13 men with O r HH (free testosterone (free T ) <225 pmol/l) and 11 age‐matched eugonadal morbidly obese men (free T > 225 pmol/l). Results Serum free T was inversely related to body weight ( R = −0·65, P < 0·0001) and rose gradually after bariatric surgery, in eugonadal as well as in O r HH men, by 30 pmol/l for every 10 kg loss of weight. In three patients, serum free T remained within the hypogonadal range despite substantial weight loss. Gonadal hormone status prior to surgery did not affect the 1‐year outcome of surgery. Conclusion Obesity‐related hypogonadotrophic hypogonadism is a reversible condition in the majority of obese men. It does not reduce the efficacy of bariatric surgery. Preoperative weight‐adjusted normal values are recommended to avoid an incorrect diagnosis of hypogonadism in obese men.